BNP Paribas Financial Markets Acquires Shares of 5,572 Astria Therapeutics, Inc. (NASDAQ:ATXS)

BNP Paribas Financial Markets acquired a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,572 shares of the biotechnology company’s stock, valued at approximately $50,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ATXS. KLP Kapitalforvaltning AS acquired a new stake in shares of Astria Therapeutics in the fourth quarter valued at $41,000. Tower Research Capital LLC TRC increased its stake in shares of Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 2,766 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of Astria Therapeutics in the fourth quarter valued at $65,000. Teacher Retirement System of Texas acquired a new stake in shares of Astria Therapeutics in the fourth quarter valued at $91,000. Finally, New York State Common Retirement Fund increased its stake in shares of Astria Therapeutics by 67.0% in the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 4,300 shares in the last quarter. 98.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ATXS shares. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $47.00 target price on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics presently has an average rating of “Buy” and an average price target of $30.00.

Astria Therapeutics Stock Up 3.8%

Shares of ATXS stock opened at $4.96 on Wednesday. The firm has a market cap of $279.91 million, a price-to-earnings ratio of -2.37 and a beta of 0.45. Astria Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $12.92. The stock has a 50-day moving average price of $4.51 and a 200 day moving average price of $6.80.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.10). Sell-side analysts predict that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.